A Pan-Cancer Analysis of Lesion-Level Treatment Response to Extend the 'Seed and Soil' Paradigm.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
087 patients enrolled in 20 clinical trials across six cancer types.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
VaPLI and immune tolerance status were significant predictors of lesion behavior. [CONCLUSIONS] Our findings support an expanded seed-soil framework that incorporates physiological and therapeutic context, enabling site-aware treatment strategies and refined patient selection for metastatic cancer therapies.
[BACKGROUND] The classical "seed and soil" hypothesis suggests that metastatic spread is shaped by tumor-intrinsic traits ("seeds") and the organ-specific microenvironment ("soil").
APA
Ian D, Jiawei Z, et al. (2025). A Pan-Cancer Analysis of Lesion-Level Treatment Response to Extend the 'Seed and Soil' Paradigm.. medRxiv : the preprint server for health sciences. https://doi.org/10.1101/2025.09.16.25335893
MLA
Ian D, et al.. "A Pan-Cancer Analysis of Lesion-Level Treatment Response to Extend the 'Seed and Soil' Paradigm.." medRxiv : the preprint server for health sciences, 2025.
PMID
41001480 ↗
Abstract 한글 요약
[BACKGROUND] The classical "seed and soil" hypothesis suggests that metastatic spread is shaped by tumor-intrinsic traits ("seeds") and the organ-specific microenvironment ("soil"). We expand this concept to explain lesion-level therapeutic responses and phenotypic variability across metastatic cancers.
[METHODS] We analyzed 55,220 lesions from 6,087 patients enrolled in 20 clinical trials across six cancer types. Using nonlinear mixed-effects modeling, we estimated lesion-specific parameters: regression rate (kkill), progression rate (kge), and resistant fraction (Fx). Multivariable Cox models, adjusted for cancer type, treatment modality, and clinical covariates, were used to assess organ-specific response patterns. Two key microenvironmental features-Vascular Perfusion and Leakiness Index (VaPLI) and tissue immune tolerance-were evaluated as predictors of lesion-level phenotypes.
[RESULTS] Treatment response dynamics varied significantly across metastatic sites, even within the same cancer type and therapy. Lesion-level responses reflected a strong seed-soil interaction, influenced by treatment modality. Liver metastases showed high initial regression but rapid progression, while bone lesions, especially in prostate cancer, exhibited more stable responses. VaPLI and immune tolerance status were significant predictors of lesion behavior.
[CONCLUSIONS] Our findings support an expanded seed-soil framework that incorporates physiological and therapeutic context, enabling site-aware treatment strategies and refined patient selection for metastatic cancer therapies.
[METHODS] We analyzed 55,220 lesions from 6,087 patients enrolled in 20 clinical trials across six cancer types. Using nonlinear mixed-effects modeling, we estimated lesion-specific parameters: regression rate (kkill), progression rate (kge), and resistant fraction (Fx). Multivariable Cox models, adjusted for cancer type, treatment modality, and clinical covariates, were used to assess organ-specific response patterns. Two key microenvironmental features-Vascular Perfusion and Leakiness Index (VaPLI) and tissue immune tolerance-were evaluated as predictors of lesion-level phenotypes.
[RESULTS] Treatment response dynamics varied significantly across metastatic sites, even within the same cancer type and therapy. Lesion-level responses reflected a strong seed-soil interaction, influenced by treatment modality. Liver metastases showed high initial regression but rapid progression, while bone lesions, especially in prostate cancer, exhibited more stable responses. VaPLI and immune tolerance status were significant predictors of lesion behavior.
[CONCLUSIONS] Our findings support an expanded seed-soil framework that incorporates physiological and therapeutic context, enabling site-aware treatment strategies and refined patient selection for metastatic cancer therapies.